Cargando…

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is a complex, inflammatory and neurodegenerative disease of the central nervous system leading to long-term disability. Recent studies indicate a close association between inflammation and neurodegeneration in all lesions and disease stages of MS. Prolyl oligopept...

Descripción completa

Detalles Bibliográficos
Autores principales: Tenorio-Laranga, Jofre, Coret-Ferrer, Francisco, Casanova-Estruch, Buenaventura, Burgal, María, García-Horsman, J Arturo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864237/
https://www.ncbi.nlm.nih.gov/pubmed/20370893
http://dx.doi.org/10.1186/1742-2094-7-23
_version_ 1782180759789895680
author Tenorio-Laranga, Jofre
Coret-Ferrer, Francisco
Casanova-Estruch, Buenaventura
Burgal, María
García-Horsman, J Arturo
author_facet Tenorio-Laranga, Jofre
Coret-Ferrer, Francisco
Casanova-Estruch, Buenaventura
Burgal, María
García-Horsman, J Arturo
author_sort Tenorio-Laranga, Jofre
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a complex, inflammatory and neurodegenerative disease of the central nervous system leading to long-term disability. Recent studies indicate a close association between inflammation and neurodegeneration in all lesions and disease stages of MS. Prolyl oligopeptidase (POP) is a proline-specific serine protease that cleaves several neuroactive peptides. This peptidase has been implicated in neurodegeneration, as well as in the modulation of the inflammatory response. METHODS: We examined plasma POP and the levels of an endogenous POP inhibitor from relapsing remitting MS patients and compared these with healthy controls, by monitoring the fluorescent changes due to standard fluorescently labelled substrate cleavage. We analysed the data in relationship to patient age and disease disability status. RESULTS: We observed a significant decrease in POP activity in plasma of relapsing remitting MS patients relative to healthy controls, coupled with an increase of POP endogenous inhibitor. The POP activity was also correlated with patient age and disability status. The lowered POP activity from plasma of MS patients could be rescued by reductants CONCLUSIONS: The decrease in circulating POP activity measured in MS is reverted by reductants. This suggests that POP inactivation in MS might be a result of the oxidative conditions prevailing in the plasma of the diseased patients. Plasma levels of POP activity as well as those of their endogenous inhibitor are suggested as biomarkers of inflammation and oxidative stress in MS.
format Text
id pubmed-2864237
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28642372010-05-05 Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis Tenorio-Laranga, Jofre Coret-Ferrer, Francisco Casanova-Estruch, Buenaventura Burgal, María García-Horsman, J Arturo J Neuroinflammation Research BACKGROUND: Multiple sclerosis (MS) is a complex, inflammatory and neurodegenerative disease of the central nervous system leading to long-term disability. Recent studies indicate a close association between inflammation and neurodegeneration in all lesions and disease stages of MS. Prolyl oligopeptidase (POP) is a proline-specific serine protease that cleaves several neuroactive peptides. This peptidase has been implicated in neurodegeneration, as well as in the modulation of the inflammatory response. METHODS: We examined plasma POP and the levels of an endogenous POP inhibitor from relapsing remitting MS patients and compared these with healthy controls, by monitoring the fluorescent changes due to standard fluorescently labelled substrate cleavage. We analysed the data in relationship to patient age and disease disability status. RESULTS: We observed a significant decrease in POP activity in plasma of relapsing remitting MS patients relative to healthy controls, coupled with an increase of POP endogenous inhibitor. The POP activity was also correlated with patient age and disability status. The lowered POP activity from plasma of MS patients could be rescued by reductants CONCLUSIONS: The decrease in circulating POP activity measured in MS is reverted by reductants. This suggests that POP inactivation in MS might be a result of the oxidative conditions prevailing in the plasma of the diseased patients. Plasma levels of POP activity as well as those of their endogenous inhibitor are suggested as biomarkers of inflammation and oxidative stress in MS. BioMed Central 2010-04-06 /pmc/articles/PMC2864237/ /pubmed/20370893 http://dx.doi.org/10.1186/1742-2094-7-23 Text en Copyright ©2010 Tenorio-Laranga et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Tenorio-Laranga, Jofre
Coret-Ferrer, Francisco
Casanova-Estruch, Buenaventura
Burgal, María
García-Horsman, J Arturo
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title_full Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title_fullStr Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title_full_unstemmed Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title_short Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
title_sort prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864237/
https://www.ncbi.nlm.nih.gov/pubmed/20370893
http://dx.doi.org/10.1186/1742-2094-7-23
work_keys_str_mv AT tenoriolarangajofre prolyloligopeptidaseisinhibitedinrelapsingremittingmultiplesclerosis
AT coretferrerfrancisco prolyloligopeptidaseisinhibitedinrelapsingremittingmultiplesclerosis
AT casanovaestruchbuenaventura prolyloligopeptidaseisinhibitedinrelapsingremittingmultiplesclerosis
AT burgalmaria prolyloligopeptidaseisinhibitedinrelapsingremittingmultiplesclerosis
AT garciahorsmanjarturo prolyloligopeptidaseisinhibitedinrelapsingremittingmultiplesclerosis